ADMS Adamas Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 21 November 2019 Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

   EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

2. 08 November 2019 Adamas Announces New Employment Inducement Grant

   EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the

3. 07 November 2019 Adamas Reports Third Quarter 2019 Financial Results

   - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with

4. 30 October 2019 Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

   EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after

5. 08 October 2019 Adamas Announces New Employment Inducement Grant

   EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

6. 27 September 2019 Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

   EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

7. 20 September 2019 Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

   EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS)

8. 17 September 2019 Adamas Announces New Employment Inducement Grant

   EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted its new Chief Executive

9. 13 September 2019 Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

   - Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) --

10. 10 September 2019 Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the